Updated on 30 June 2015
First, could you give the readers a short bio of your company?
Cyfuse is a regenerative medicine startup founded in 2010 to develop its proprietary technology to assemble living cells in three dimensions. Cyfuse has been developing this technology until now with the support of the Japan Science and Technology Agency (JST) and the New Energy and Industrial Technology Development Organization (NEDO).
In 2010, Cyfuse began working with Shibuya Kogyo Co., Ltd. to jointly develop a bio 3D printer called ‘Regenova' that automatically assembles cellular aggregates. Shipment of Regenova to Japanese universities began in 2013. Cyfuse's main business activities include the sales of Regenova bio 3D printers, R&D of 3D tissue products, and subcontract manufacturing of 3D tissue products.
Cyfuse is based in Tokyo and is headed by President and CEO Koji Kuchiishi.
Our goal is to facilitate innovative therapeutic approaches through our new bioengineering technologies to make regenerative medicine a reality for patients around the world.
How has Cyfuse taken tissue engineering to an advanced next-gen level?
Cyfuse works on prototyping various tissues into 3D shapes for future clinical application. Cyfuse's 3D tissue construction technology has unique and break-through making features for research and regenerative medicine. Our ‘Kenzan' method enables us to construct 3-dimensional tissue without using scaffold material. In addition, the method can provide the suitable maturation environment for the cells to self-reorganize into the proper arrangement as living tissue. In order to ease usage of this technology, we have developed the bio 3D printer, Regenova. With Regenova, researchers now have the possibility to design and make the desired tissue in laboratory.
The company's technology uses a fine needle array to skewer cellular aggregates (0.5mm diameter), which are then stacked three dimensionally. Once the cellular aggregates are fused together, the needles are removed, resulting in elastic tissue based on the original cells and the collagen within. The Regenova bio 3D printer can automatically create a 3D cellular structure by inputting 3D data and cellular aggregate material. The resulting cellular structure spends several days or weeks maturing in a customized bioreactor, and comes to express its target strength and function. This technology can be used with various cell types, and is able to produce thicker and more elastic tissue than was conventionally possible, so it is expected to bring breakthroughs in drug discovery research and regenerative medicine in a wide range of therapeutic areas.
What are the tissues/organs developed by Cyfuse's in-house technology?
Cartilage/bone, vascular tube, liver, neural cells are the key tissues that are developed by our in-house technology.